<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05015270</url>
  </required_header>
  <id_info>
    <org_study_id>NMU20211033</org_study_id>
    <nct_id>NCT05015270</nct_id>
  </id_info>
  <brief_title>Correlation of Biomarkers With the Presence and Severity of Coronary Artery Disease</brief_title>
  <acronym>PREDICTION-NJ</acronym>
  <official_title>Identification of Peripheral Blood Biomarkers for Prediction of Coronary Artery Disease Confirmed by Coronary Angiography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing First Hospital, Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing First Hospital, Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The development of coronary artery disease is multifactorial. Peripheral blood biomarkers&#xD;
      paly an important role in the prediction of coronary artery disease. However, the&#xD;
      identification of those biomarkers and their correlation with the presence and severity of&#xD;
      coronary artery disease are unclear. The present study aims to identify the differentially&#xD;
      expressed biomarkers from peripheral blood between normal population and patients with&#xD;
      different disease burden confirmed by coronary angiography, and to analyze the correlation of&#xD;
      those biomarkers with the severity of coronary artery disease. Finally, the prediction of&#xD;
      biomarkers for clinical events.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study includes three parts:&#xD;
&#xD;
        1. Part 1 (Pilot analysis): 30 normal people and 30 patients with at least one epicardial&#xD;
           coronary artery disease confirmed by angiography will be included. 10 ml peripheral&#xD;
           blood from arterial sheath (just before angiography) will be collected in each subject.&#xD;
           Proteomics analyses are performed in order to obtain the differentially expressed&#xD;
           proteins (coded by Proteins 1-x.&#xD;
&#xD;
        2. Part 2 (Training group): Differentially expressed Proteins 1-x are measured and compared&#xD;
           between patients with diameter stenosis &lt;70% (n=100) vs. with diameter stenosis ≥&#xD;
           70%(n=100), respectively. Finally, Proteins 1-y from Proteins 1-x will be identified.&#xD;
           Subgroups stratified by single-, double-, and triple-vessel disease will be performed.&#xD;
&#xD;
        3. Part 3 (Validation group): The difference in blood concentration of Proteins 1-y between&#xD;
           patients with different disease burden will be further analyzed: patients with diameter&#xD;
           stenosis &lt;70% (n=200) vs. diameter stenosis ≥70% (n=200), respectively. Subgroups&#xD;
           stratified by single-, double-, and triple-vessel disease will be performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 21, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 27, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation of biomarkers with coronary artery disease burden</measure>
    <time_frame>12 months</time_frame>
    <description>We will analyze the differential level of proteins in peripheral blood between three groups. As a result, the correlation between biomarkers with disease burden will analyzed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical events</measure>
    <time_frame>12 months</time_frame>
    <description>Clinical events are a composite of cardiac death, myocardial infarction, revascularization, and stroke at one-year since coronary angiography</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Less disease group</arm_group_label>
    <description>Patients with coronary artery diameter stenosis &lt;70% confirmed by coronary angiography;&#xD;
Patients will be treated using guideline recommended medications or percutaneous coronary intervention at physician's discretion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe disease group</arm_group_label>
    <description>Patients with coronary artery stenosis ≥70% confirmed by coronary angiography;&#xD;
Patients will be treated using guideline recommended medications or percutaneous coronary intervention at physician's discretion</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Medications or percutaneous coronary intervention</intervention_name>
    <description>In this study, we will for the first analyze the correlation of proteins concentration with coronary artery disease burden. Next, the prediction of proteins for one-year clinical events will be further analyzed</description>
    <arm_group_label>Less disease group</arm_group_label>
    <arm_group_label>Severe disease group</arm_group_label>
    <other_name>Percutaneous coronary intervention</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral blood will be collected from all patients after informal consent is obtained&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        In geneal, the traditional risk factors for coronary artery disease (including age, sex,&#xD;
        hypertension, diabetes, dyslipidemia, peripheral artery disease, smoker, fat, etc.) will be&#xD;
        comparble between three groups (case-control).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  For Pilot study, both health and patients with at least one epicardial coronary artery&#xD;
             disease are included&#xD;
&#xD;
          -  For both Training group and Validation group, patients must have at least one&#xD;
             epicardial coronary artery disease&#xD;
&#xD;
          -  Left ventricular ejection fraction &gt; 30%&#xD;
&#xD;
          -  Stable or unstable angina&#xD;
&#xD;
          -  Myocardial infarction older than 1 month&#xD;
&#xD;
          -  No active inflammation&#xD;
&#xD;
          -  No scheduled non-cardiac surgery within 12 months&#xD;
&#xD;
          -  eGFR &gt; 30 ml/min/m2&#xD;
&#xD;
          -  Patients agree to participate in this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe liver dysfunction&#xD;
&#xD;
          -  Blood platelet count &lt;100 x 109/L&#xD;
&#xD;
          -  Cancer&#xD;
&#xD;
          -  On dialysis&#xD;
&#xD;
          -  Pulmonary hypertension (defined as mean pulmonary arterial pressure &gt; 25 mmHg and&#xD;
             pulmonary vessel resistance &gt; 3.0 Woods Unit)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shao-Liang M Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital with Nanjing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dandan M Zhu, MBBS</last_name>
    <phone>+86-25-52271341</phone>
    <email>chmengx@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hongjuan F Peng, MBBS</last_name>
    <phone>+86-25-52271341</phone>
    <email>ryophj@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nanjing First Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuli M Zhao, MD</last_name>
      <phone>+86-25-52271003</phone>
      <email>shuliz@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Ling F Lin, MD</last_name>
      <phone>+86-25-52271--9</phone>
      <email>linling@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jun-Jie M Zhang, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fei M Ye, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ling F Lin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yue F Gu, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wenying F Zhou, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jing F Kan, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jinque F Luo, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhen M Ge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiaobo M Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiaofei M Gao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiangquan M Kong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Minghui F Li, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan F Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Linlin F Zhu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 18, 2021</study_first_submitted>
  <study_first_submitted_qc>August 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2021</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing First Hospital, Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Shaoliang Chen, MD</investigator_full_name>
    <investigator_title>Director of Cardiology and Cath Lab, Vice President of Nanjing First Hospital</investigator_title>
  </responsible_party>
  <keyword>Biomarkers, Coronary artery disease, Disease burden, Clinical events</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No share IPD with others</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

